Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/18/2006 First Published: 6/25/2005


1.		Phase III Randomized Chemoprevention Study of Eflornithine and Sulindac in Patients With a History of Adenomatous Polyps of the Colon

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention				Closed				40 to 80				NCI				UCIRVINE-UCI-2002-2261 NCT00118365

Last Modified: 5/1/1999 First Published: 11/1/1997


2.		Phase II Clinical Trial of Sulindac, a Nonsteroidal Antiinflammatory Agent, for Chemoprevention of Colorectal Neoplasia (Summary Last Modified 05/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Closed				18 to 80				NCI				CPMC-IRB-1095-072 NCI-P97-0110

Last Modified: 4/1/2003 First Published: 6/1/2000


3.		Phase IIB Randomized Study of Eflornithine (DFMO) and Sulindac in the Prevention of Colorectal Carcinoma in Patients With Previously Resected Colorectal Adenoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Closed				40 to 80				NCI				UCIRVINE-97-05 NCI-P00-0150, NCT00005882

Last Modified: 4/9/2004 First Published: 6/1/2002


4.		Phase II Study of Sulindac and Docetaxel in Women With Metastatic or Recurrent Adenocarcinoma of the Breast

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				FCCC-01031 FCCC-63723, NCI-G02-2080, NCT00039520

Last Modified: 12/1/1994


5.		Phase II Randomized, Placebo-Controlled Trial of Sulindac for Chemoprevention of Pre-malignant Colorectal Adenomas (Summary Last Modified 12/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Closed				30 to 80								UUMC-9102 NCI-P92-0018

Last Modified: 6/1/2005 First Published: 5/23/2003


6.		Phase II Randomized Study of Sulindac Versus Aspirin Versus Ursodiol for the Prevention of Colorectal Cancer in Patients With Aberrant Crypt Foci and a History of Colorectal Carcinoma or Adenoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Closed				40 to 80				NCI				MDA-ID-01454 NCT00062023

Last Modified: 9/19/2008 First Published: 6/2/2006


7.		Phase II Randomized Chemoprevention Study of Atorvastatin Versus Oligofructose-Enriched Inulin (Raftilose Synergy 1) Versus Sulindac in Patients at Increased Risk of Developing Sporadic Colorectal Neoplasia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Prevention				Temporarily closed				40 and over				NCI				MAYO-030103 MAY03-1-03, MAYO-1395-05, NCT00335504

Last Modified: 6/18/2007 First Published: 10/21/2005


8.		Phase I Study of Sulindac in Women at High Risk for Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Prevention				Closed				18 to 65				NCI				UARIZ-UAZ04-2-02 UARIZ-HSC-0553, UAZ04-2-02, NCT00245024

Last Modified: 5/21/2007 First Published: 9/1/1998


9.		Randomized Study of Three Plant Phenolic Compounds Versus Sulindac (Part A) or Curcumin (Part B) in Prevention of Colon Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Prevention				Temporarily closed				18 and over				Other				RUH-SSH-190-0600 RUH-SSH-190-0698, NCI-V98-1425, NCT00003365

Last Modified: 10/1/1992


10.		Randomized Placebo-Controlled, Double-Blind Study in the Prevention of Colorectal Adenocarcinoma with Sulindac in Patients with Multiple Polyposis (Summary Last Modified 10/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Prevention				Closed				18 and older				NCI				NCCTG-909251 MAYO-909251, NCI-P91-0011

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute